Considering its higher binding affinity to VEGFR-2 compared with other anti-angiogenic drugs, apatinib might be able to offer further potential therapeutic opportunities for treating advanced cholangiocarcinoma, especially for patients with high expression of VEGF (34). This evidence concerns the gene KDR and cholangiocarcinoma.